Hyderabad, Jan 27 (PTI) Bharat Biotech (BBIL) has tied up
with pharma major GSK, and PATH, a global team of innovators
working to accelerate health equity, for GSKs malaria
vaccine, RTS,S/AS01E1, the city-based vaccine maker said here
The agreement includes the transfer of manufacturing of
the RTS,S antigen part of the vaccine and the grant of a
license on all rights pertaining to the RTS,S/AS01 malaria
vaccine to Bharat Biotech, while GSK would retain the
production of the adjuvant of the vaccine (AS01E) and supply
it to BBIL, the company said in a press release.
BBIL was selected through a comprehensive, competitive
process undertaken by GSK and PATH, working in consultation
with the World Health Organization, it said.
The RTS,S/AS01E malaria vaccine, developed by GSK for
more than 30 years, and in partnership with PATH since 2001,is
currently being piloted in regions of Ghana, Kenya, and Malawi
under the Malaria Vaccine Implementation Programme (MVIP).
Thomas Breuer, GSK Vaccines Chief Medical Officer and
Vaccines Global Health lead said: "With a child still dying of
malaria every two minutes, helping secure the long-term future
of the only vaccine available by working with an established
leader like Bharat Biotech is vital for the continued fight
against this devastating disease.
GSK is delighted to sign this agreement with Bharat
John Bawa, Africa Lead, Vaccine Implementation, PATH,
said "Now, with the signing of this agreement with Bharat
Biotech, we have an additional, new partner to help ensure
that this vaccine can be more widely available for use in
Africa, alongside other malaria interventions, in the years to
Krishna M Ella, Bharat Biotech, Chairman and Managing
Director said: "We salute the commitment by GSK, PATH, and
partners, in developing a novel vaccine against malaria, a
dreaded disease with more than 200 million cases worldwide.
We are truly honoured to support this partnership and to
provide global access to RTS,S/AS01E.
With prior expertise in malaria research,WHO pre-
qualified vaccines, supplied to more than 70 countries, Bharat
Biotech is geared up for large-scale manufacturing, and to
provide continuous long-term supply of this life-saving
vaccine". PTI GDK APR
Disclaimer :- This story has not been edited by Outlook staff and is auto-generated from news agency feeds. Source: PTI
More from Outlook Magazine